# An independent reading desk for the growth hormone axis > About steroidnpeptides — Reading the Growth Hormone Axis Research Peptides Literature — About steroidnpeptides: an independent digest of the Growth Hormone Axis research peptides literature — what it covers, what it refuses to cover, how citations are handled, and why the name says what it says. **ABOUT THIS DESK** What this site is, what it will not do, and how to read the brackets. ## What this is steroidnpeptides is an independent literature digest covering three compounds that act on the growth hormone axis: ipamorelin, CJC-1295 and tesamorelin. It is not a clinic, not a pharmacy, not a supplier and not affiliated with any manufacturer, prescriber or seller of anything described here. The editorial method is deliberately narrow. Each compound gets a page assembled from the peer-reviewed record — mechanism, the studies that exist, the species those studies used, the endpoints they measured, and the safety questions the literature itself raises. Where community reports are summarised, they are labelled as anecdote and carry no amounts. Where evidence is absent, the absence is stated in the sentence rather than glossed over. The compounds were not chosen for variety. They share an axis and split cleanly across its two upstream receptors, which makes them genuinely comparable — and their evidence bases turn out to be about as far apart as three compounds in one class can be. That contrast is the reason the desk exists. ## The name, and what follows from it The domain name pairs two categories that people search for in the same breath. It is a description of a search behaviour, not a statement of what this site covers. Anabolic-androgenic steroids are a controlled-substance class. This desk carries nothing about obtaining them, using them, combining them, cycling them, or working around any legal restriction on them, and it does not present any peptide covered here as an alternative to them, a milder version of them, or a component of anything involving them. Those are not omissions pending a future article; they are the editorial boundary. What the desk offers instead is the more interesting thing: what the growth hormone axis literature actually studies once the performance frame is set aside. That literature turns out to be about postoperative recovery, about visceral adipose tissue in a fat-redistribution syndrome, about hormone half-lives measured in supervised volunteers, about bone growth in rats and chemotherapy weight loss in ferrets. It is a real and substantial body of work, and almost none of it is about what these compounds are popularly assumed to be for. Reporting that honestly is more useful than pretending otherwise. ## How to read the brackets Every bracketed number in the text resolves to a numbered entry on the references page, each with a full citation and, where one exists, a digital object identifier or a link to the record. Numbers are stable across the site: a citation carries the same number on every page. Quantitative claims always carry a bracket. Percentages, participant counts, durations, effect sizes, confidence intervals and half-lives are traceable to the study that produced them, and the sentence names the species and the population wherever that matters — which, in this field, is almost always. A finding in a ferret is reported as a finding in a ferret [1]. A result in adults with HIV-associated lipodystrophy is reported as a result in that population [13]. Statements about mechanism that carry no number are descriptions of receptor pharmacology drawn from the same source corpus, and they are written so that they make no quantitative claim. If a sentence gives a number without a bracket, that is an error worth reporting to the desk. ## Editorial stance Three commitments govern everything published here. First, no dosing and no medical advice. Doses used in cited studies are reported as part of those studies, because a trial's dose is part of its finding. Nothing here is a recommendation, a schedule or a protocol, and no sentence on this site tells a reader what to do. Second, gaps get named. The most common failure in writing about research peptides is presenting mechanism as though it were outcome — describing what a molecule does at a receptor and letting the reader assume that a clinical benefit follows. It frequently does not. Ipamorelin's only controlled trial of a clinical outcome failed [3]; that fact belongs at the top of a page about ipamorelin, not in a footnote at the bottom. Third, no commerce. This desk does not sell, does not link to sellers, does not name suppliers and takes no position on where anything might be obtained. Its only product is a reading of the literature, and its only claim on a reader's attention is that the citations are real and the numbers match the papers. --- A reference desk on the growth hormone axis: it reports what the trials measured and names the species they measured it in, and it covers neither anabolic pharmacology nor any way of obtaining anything.